LAG3 and neoplasm: This immune scenario was paralleled by a remarkable increase in the fraction of Ki67 + and granzyme-B double-positive cells in CD4+ (3.8% pre vs 12.7% post) and CD8+ (5% pre vs 9.4% post) T lymphocytes, as well as in both the CD56high (16.2% pre vs 35% post) and CD56dim (6.4% pre vs 20.8% post) NK cell subsets (Fig. 4C), which suggests the ability of PD-1 and LAG3 blockade to unleash proliferating and cytotoxic anti-tumor effectors.